HAYA Therapeutics Raises USD 65 Million in Series A Funding

Haya Therapeutics SA, a biotechnology company, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital and included, among others, Eli Lilly and Company.

Lenz & Staehelin acted for Eli Lilly. The team included Tino Gaberthüel, Patrick Schärli, Arnold Romero and Kaan Saritas (all M&A), Lukas Aebi (Tax) and Franziska Stadtherr-Glättli (Management Incentive Plans).